The global critical care drugs market size accounted for USD 1.16 billion in 2024, grew to USD 1.22 billion in 2025 and is expected to be worth around USD 1.91 billion by 2034, registering a CAGR of 5.12% between 2024 and 2034.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Critical Care Drugs Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Critical Care Drugs Market Revenue and Volume, By Drug Type, 2024-2034
8.1.1 Opioids
8.1.1.1. Market Revenue and Volume Forecast (2021-2034)
8.1.2. Morphine
8.1.2.1. Market Revenue and Volume Forecast (2021-2034)
8.1.3. Pethidine
8.1.3.1. Market Revenue and Volume Forecast (2021-2034)
8.1.4. Naloxone
8.1.4.1. Market Revenue and Volume Forecast (2021-2034)
8.1.5. Fentanyl
8.1.5.1. Market Revenue and Volume Forecast (2021-2034)
8.1.6. Benzodiazepines
8.1.6.1. Market Revenue and Volume Forecast (2021-2034)
8.1.7. Diazepam
8.1.7.1. Market Revenue and Volume Forecast (2021-2034)
8.1.8. Midazolam
8.1.8.1. Market Revenue and Volume Forecast (2021-2034)
8.1.9. Lorazepum
8.1.9.1. Market Revenue and Volume Forecast (2021-2034)
8.1.10. Flumazenil
8.1.10.1. Market Revenue and Volume Forecast (2021-2034)
8.1.11. Sedatives
8.1.11.1. Market Revenue and Volume Forecast (2021-2034)
8.1.12. Anesthetics
8.1.12.1. Market Revenue and Volume Forecast (2021-2034)
8.1.13. Others
8.1.13.1. Market Revenue and Volume Forecast (2021-2034)
9.1. Critical Care Drugs Market Revenue and Volume, By End-user, 2024-2034
9.1.1. Intensive Care Unit (ICU)
9.1.1.1. Market Revenue and Volume Forecast (2021-2034)
9.1.2. Coronary Care Unit (CCU)
9.1.2.1. Market Revenue and Volume Forecast (2021-2034)
9.1.3. Operation Theatres
9.1.3.1. Market Revenue and Volume Forecast (2021-2034)
9.1.4. Trauma Centers
9.1.4.1. Market Revenue and Volume Forecast (2021-2034)
10.1. North America
10.1.1. Market Revenue and Volume Forecast, By Drug Type (2021-2034)
10.1.2. Market Revenue and Volume Forecast, By End-user (2021-2034)
10.1.3. U.S.
10.1.3.1. Market Revenue and Volume Forecast, By Drug Type (2021-2034)
10.1.3.2. Market Revenue and Volume Forecast, By End-user (2021-2034)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Volume Forecast, By Drug Type (2021-2034)
10.1.4.2. Market Revenue and Volume Forecast, By End-user (2021-2034)
10.2. Europe
10.2.1. Market Revenue and Volume Forecast, By Drug Type (2021-2034)
10.2.2. Market Revenue and Volume Forecast, By End-user (2021-2034)
10.2.3. UK
10.2.3.1. Market Revenue and Volume Forecast, By Drug Type (2021-2034)
10.2.3.2. Market Revenue and Volume Forecast, By End-user (2021-2034)
10.2.4. Germany
10.2.4.1. Market Revenue and Volume Forecast, By Drug Type (2021-2034)
10.2.4.2. Market Revenue and Volume Forecast, By End-user (2021-2034)
10.2.5. France
10.2.5.1. Market Revenue and Volume Forecast, By Drug Type (2021-2034)
10.2.5.2. Market Revenue and Volume Forecast, By End-user (2021-2034)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Volume Forecast, By Drug Type (2021-2034)
10.2.6.2. Market Revenue and Volume Forecast, By End-user (2021-2034)
10.3. APAC
10.3.1. Market Revenue and Volume Forecast, By Drug Type (2021-2034)
10.3.2. Market Revenue and Volume Forecast, By End-user (2021-2034)
10.3.3. India
10.3.3.1. Market Revenue and Volume Forecast, By Drug Type (2021-2034)
10.3.3.2. Market Revenue and Volume Forecast, By End-user (2021-2034)
10.3.4. China
10.3.4.1. Market Revenue and Volume Forecast, By Drug Type (2021-2034)
10.3.4.2. Market Revenue and Volume Forecast, By End-user (2021-2034)
10.3.5. Japan
10.3.5.1. Market Revenue and Volume Forecast, By Drug Type (2021-2034)
10.3.5.2. Market Revenue and Volume Forecast, By End-user (2021-2034)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Volume Forecast, By Drug Type (2021-2034)
10.3.6.2. Market Revenue and Volume Forecast, By End-user (2021-2034)
10.4. MEA
10.4.1. Market Revenue and Volume Forecast, By Drug Type (2021-2034)
10.4.2. Market Revenue and Volume Forecast, By End-user (2021-2034)
10.4.3. GCC
10.4.3.1. Market Revenue and Volume Forecast, By Drug Type (2021-2034)
10.4.3.2. Market Revenue and Volume Forecast, By End-user (2021-2034)
10.4.4. North Africa
10.4.4.1. Market Revenue and Volume Forecast, By Drug Type (2021-2034)
10.4.4.2. Market Revenue and Volume Forecast, By End-user (2021-2034)
10.4.5. South Africa
10.4.5.1. Market Revenue and Volume Forecast, By Drug Type (2021-2034)
10.4.5.2. Market Revenue and Volume Forecast, By End-user (2021-2034)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Volume Forecast, By Drug Type (2021-2034)
10.4.6.2. Market Revenue and Volume Forecast, By End-user (2021-2034)
10.5. Latin America
10.5.1. Market Revenue and Volume Forecast, By Drug Type (2021-2034)
10.5.2. Market Revenue and Volume Forecast, By End-user (2021-2034)
10.5.3. Brazil
10.5.3.1. Market Revenue and Volume Forecast, By Drug Type (2021-2034)
10.5.3.2. Market Revenue and Volume Forecast, By End-user (2021-2034)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Volume Forecast, By Drug Type (2021-2034)
10.5.4.2. Market Revenue and Volume Forecast, By End-user (2021-2034)
11.1. Pfizer Inc
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Abbott
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Cadila Pharmaceutica
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Cambrex Corporation
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Triveni Chemicals
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Haffkine Bio-Pharmaceutical Corporation Ltd
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Neon Laboratories Limited
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
13.1. About Us
13.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample